Literature DB >> 24262589

Diets and nonalcoholic fatty liver disease: the good and the bad.

Mohamed Asrih1, François R Jornayvaz2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is now described as the hepatic manifestation of the metabolic syndrome and is the most frequent chronic liver disease, affecting about one out of three people in the western world. NAFLD is strongly linked to insulin resistance, which represents a key risk factor for the development of type 2 diabetes. To date, there are no reliable and efficient pharmacotherapies in the treatment of NAFLD. However, obesity, which represents one of the main features of the metabolic syndrome, is strongly associated with NAFLD. Therefore, lifestyle modifications, i.e. weight loss and increased physical activity, are the very first clinical approaches aiming at treating NAFLD. However, although weight loss is beneficial in NAFLD, certain diets known to induce weight loss can actually cause or exacerbate this disease, and therefore induce insulin resistance, such as very low carbohydrate, high fat diets. Moreover, macronutrient diet composition can impact NAFLD without any change in body weight. Indeed, diets rich in fatty acids, particularly saturated, or in refined carbohydrates such as those found in soft drinks, can actually exacerbate NAFLD. The aim of this review is to discuss the role of weight loss and macronutrients modifications, particularly the role of fat and carbohydrate diet composition, in the treatment of NAFLD.
Copyright © 2013 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Carbohydrates; Diet; Fats; Fatty acids; Insulin resistance; NAFLD

Mesh:

Substances:

Year:  2013        PMID: 24262589     DOI: 10.1016/j.clnu.2013.11.003

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  54 in total

1.  High dietary intake of palm oils compromises glucose tolerance whereas high dietary intake of olive oil compromises liver lipid metabolism and integrity.

Authors:  Youzan Ferdinand Djohan; Eric Badia; Beatrice Bonafos; Gilles Fouret; Céline Lauret; Anne-Marie Dupuy; Edith Pinot; Thibault Sutra; Sylvie Gaillet; Karen Lambert; Fabrice Raynaud; Nathalie Gayrard; Bernard Jover; Absalome Aké Monde; Jean Paul Cristol; Charles Coudray; Christine Feillet-Coudray
Journal:  Eur J Nutr       Date:  2018-11-03       Impact factor: 5.614

2.  Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model.

Authors:  Reilly T Enos; Kandy T Velázquez; Jamie L McClellan; Taryn L Cranford; Michael D Walla; E Angela Murphy
Journal:  Nutr Res       Date:  2015-04-11       Impact factor: 3.315

3.  The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial.

Authors:  Zahra Yari; Makan Cheraghpour; Seyed Moayed Alavian; Mehdi Hedayati; Hassan Eini-Zinab; Azita Hekmatdoost
Journal:  Eur J Clin Nutr       Date:  2020-07-09       Impact factor: 4.016

4.  High-Lard and High-Cholesterol Diet, but not High-Lard Diet, Leads to Metabolic Disorders in a Modified Dyslipidemia Model.

Authors:  Lidiane B Muniz; Aline M Alves-Santos; Fabricio Camargo; Danieli Brolo Martins; Mara Rubia N Celes; Maria Margareth V Naves
Journal:  Arq Bras Cardiol       Date:  2019-11       Impact factor: 2.000

Review 5.  Dietary Modulation of the Epigenome.

Authors:  Folami Y Ideraabdullah; Steven H Zeisel
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 6.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

7.  Low fat but not soy protein isolate was an effective intervention to reduce nonalcoholic fatty liver disease progression in C57BL/6J mice: monitored by a novel quantitative ultrasound (QUS) method.

Authors:  Joe L Rowles; Aiguo Han; Rita J Miller; Jamie R Kelly; Catherine C Applegate; Matthew A Wallig; William D O'Brien; John W Erdman
Journal:  Nutr Res       Date:  2018-12-14       Impact factor: 3.315

Review 8.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 9.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 10.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.